Mechanistic insights into LSD actions at 5-HT2A serotonin receptors
LSD 对 5-HT2A 血清素受体作用的机制见解
基本信息
- 批准号:10112869
- 负责人:
- 金额:$ 63.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-01 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:AgonistAntipsychotic AgentsArrestinsBasic ScienceBehaviorBehavioralBinding SitesBrainCRISPR/Cas technologyCellsComplexDiseaseDopamineDrug abuseG-Protein-Coupled ReceptorsGTP-Binding Protein alpha Subunits, GsGTP-Binding ProteinsGoalsGroomingHTR2A geneHallucinationsHallucinogensHeadHigh School StudentHumanHyperactivityIn VitroIndividualKineticsKnockout MiceLeadLifeLigand BindingLysergic Acid DiethylamideMediatingModelingMolecularMouse StrainsMusMutateNeuronsNoseOutcomePaperPathway interactionsPharmaceutical PreparationsPharmacologyPhysiologicalPlayPopulationPrevalencePsychosesReceptor ActivationReportingResearchResolutionRoleScienceSerotoninSerotonin Receptor 5-HT2ASerotonin Receptor 5-HT2BSignal PathwaySignal TransductionSite-Directed MutagenesisStereotypingStructureSurveysTestingTimeWalkingWild Type Mousearrestin 1behavioral responsebehavioral studybeta-arrestindrug of abuseexperimental studyextracellularin vivoinsightmolecular modelingmutantnovelnovel therapeuticsprepulse inhibitionreceptorresponseserotonin receptorside effect
项目摘要
Mechanistic insights into LSD actions at 5-HT2A-serotonin receptors LSD (lysergic acid diethylamide) -- the prototypical hallucinogen -- continues to be a frequently abused psychotomimetic agent with a life-time prevalence as high as 10.9% among all individual surveyed and as high as 3% among high school students. LSD has a complex pharmacology with significant interactions with dozens of G-protein coupled receptors (GPCRs) and it exerts primary actions at serotonin 2A (5-HT2A) receptors. Various experiments have shown that ligand binding to G protein-coupled receptors (GPCRs) can
activate, inhibit, or exert no effects on the G protein-dependent signaling pathway while having similar or diverse actions on a G protein-independent pathway through β-arrestin (βARR). In brain, these actions can be mediated through βARR 1 and/or 2. In recent papers in Science and Cell, the Roth lab has reported that LSD is a potent βARR-biased 5-HT2A receptor agonist. In preliminary experiments with wild-type mice, we find that LSD produces hyperactivity in the open field, it disrupts prepulse inhibition, and stimulates repetitive and stereotyped responses (head-twitch, nose-pokes, retrograde walking, unsupported rearing, and grooming). In contrast, the hyperactivity is blunted and the other behaviors are abrogated in the global βARR2 knockout mice. Nevertheless, additional physiological and behavioral responses have been ascribed to LSD that may also involve G proteins or βARR1. The Overall Goal of the proposed research is to clarify the role of βARR in mediating the actions of LSD at 5-HT2A receptors in vitro and in vivo. Our Central Hypothesis is that βARR-mediated signaling through 5-HT2A receptors will play a major role in many responses to LSD. Relevance: We have already reported on the antipsychotic effects βARR-biased dopamine 2 receptor compounds exert on behavior. We have evidence that some of behavioral effects of LSD are mediated at least through βARR2. With various strains of mice we will define a role for βARR1 and βARR2 signaling through 5-HT2A receptors and, thereby, reveal how activation of this receptor may underlie hallucinations in humans.
LSD(麦角酸二乙胺)——一种典型的致幻剂——仍然是一种经常被滥用的拟精神药物,在所有被调查的个体中,终生患病率高达10.9%,在高中生中高达3%。LSD具有复杂的药理作用,与数十种g蛋白偶联受体(gpcr)相互作用,主要作用于5-羟色胺2A (5-HT2A)受体。各种实验表明配体结合G蛋白偶联受体(gpcr)可以
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bryan L. Roth其他文献
A novel ligand selectively visualizes and activates chemogenetic receptors in non-human primates
一种新型配体选择性地可视化和激活非人类灵长类动物的化学遗传受体
- DOI:
- 发表时间:
2020 - 期刊:
- 影响因子:0
- 作者:
永井裕司;宮川尚久;Xi-Ping Haung;Samuel T. Slocum;Yan Xiong;堀由紀子;小山佳;季斌;平林敏行;藤本淳;三村喬生;Justin G. English;Jing Liu;井上謙一;熊田勝志;関千江;張明栄;須原哲也;高田昌彦;樋口真人;Jian Jin;Bryan L. Roth;南本敬史;Yuji Nagai - 通讯作者:
Yuji Nagai
236 - Regulation of the internalization of the 5HT<sub>2A</sub> receptor in vitro
- DOI:
10.1016/s0920-9964(97)82244-x - 发表时间:
1997-01-01 - 期刊:
- 影响因子:
- 作者:
Sally A. Berry;Laith Alsayegh;Bryan L. Roth - 通讯作者:
Bryan L. Roth
PS I-10
- DOI:
10.1016/s1734-1140(11)70453-4 - 发表时间:
2011-12-30 - 期刊:
- 影响因子:3.800
- 作者:
Jakub Fichna;Kevin Lewellyn;Feng Yan;Bryan L. Roth;Jordan K. Zjawiony - 通讯作者:
Jordan K. Zjawiony
High-dose olanzapine for treatment-resistant schizophrenia.
高剂量奥氮平治疗难治性精神分裂症。
- DOI:
10.4088/jcp.v69n0201 - 发表时间:
2008 - 期刊:
- 影响因子:0
- 作者:
Bryan L. Roth - 通讯作者:
Bryan L. Roth
Structure-Based Discovery of a NPFF1R Antagonist with Analgesic Activity
基于结构的具有镇痛活性的 NPFF1R 拮抗剂的发现
- DOI:
10.1101/2023.10.25.564029 - 发表时间:
2023 - 期刊:
- 影响因子:0
- 作者:
Brian J. Bender;J. E. Pickett;J. Braz;Hye Jin Kang;Stefan Gahbauer;Karnika Bhardwaj;Sian Rodriguez;Yongfeng Liu;Manish K. Jain;Allan I Basbaum;Bryan L. Roth;B. Shoichet - 通讯作者:
B. Shoichet
Bryan L. Roth的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bryan L. Roth', 18)}}的其他基金
Mechanistic insights into LSD actions at 5-HT2A serotonin receptors
LSD 对 5-HT2A 血清素受体作用的机制见解
- 批准号:
10550420 - 财政年份:2023
- 资助金额:
$ 63.55万 - 项目类别:
STRUCTURE AND FUNCTION OF MRG-FAMILY RECEPTORS
MRG 家族受体的结构和功能
- 批准号:
10419804 - 财政年份:2022
- 资助金额:
$ 63.55万 - 项目类别:
STRUCTURE AND FUNCTION OF MRG-FAMILY RECEPTORS
MRG 家族受体的结构和功能
- 批准号:
10593175 - 财政年份:2022
- 资助金额:
$ 63.55万 - 项目类别:
Mechanistic insights into LSD actions at 5-HT2A serotonin receptors
LSD 对 5-HT2A 血清素受体作用的机制见解
- 批准号:
10356900 - 财政年份:2018
- 资助金额:
$ 63.55万 - 项目类别:
Mechanistic insights into LSD actions at 5-HT2A serotonin receptors
LSD 对 5-HT2A 血清素受体作用的机制见解
- 批准号:
9496860 - 财政年份:2018
- 资助金额:
$ 63.55万 - 项目类别:
Molecular Details of Psychoactive Drug Actions
精神活性药物作用的分子细节
- 批准号:
10557802 - 财政年份:2017
- 资助金额:
$ 63.55万 - 项目类别:
相似海外基金
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
- 批准号:
10661090 - 财政年份:2022
- 资助金额:
$ 63.55万 - 项目类别:
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
- 批准号:
10501196 - 财政年份:2022
- 资助金额:
$ 63.55万 - 项目类别:
Possible mechanism of action of metabolic syndrome induction in patients treated with atypical antipsychotic agents
使用非典型抗精神病药物治疗的患者诱导代谢综合征的可能作用机制
- 批准号:
22590157 - 财政年份:2010
- 资助金额:
$ 63.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The use of atypical antipsychotic agents and the risk of breast cancer
非典型抗精神病药物的使用和乳腺癌的风险
- 批准号:
192724 - 财政年份:2009
- 资助金额:
$ 63.55万 - 项目类别:
Operating Grants
Indolobenzox- and Thiazepines as Atypical Antipsychotic Agents
吲哚苯氧和硫氮卓类药物作为非典型抗精神病药
- 批准号:
7539253 - 财政年份:2008
- 资助金额:
$ 63.55万 - 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
- 批准号:
7676049 - 财政年份:2007
- 资助金额:
$ 63.55万 - 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
- 批准号:
7626881 - 财政年份:2007
- 资助金额:
$ 63.55万 - 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
- 批准号:
7333930 - 财政年份:2007
- 资助金额:
$ 63.55万 - 项目类别:
Muscarinic receptor activators as antipsychotic agents
作为抗精神病药物的毒蕈碱受体激活剂
- 批准号:
7034693 - 财政年份:2006
- 资助金额:
$ 63.55万 - 项目类别:
Muscarinic receptor activators as novel antipsychotic agents
毒蕈碱受体激活剂作为新型抗精神病药
- 批准号:
7163800 - 财政年份:2006
- 资助金额:
$ 63.55万 - 项目类别:














{{item.name}}会员




